Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | $102.7M | $160.9M | $216.4M | $199.0M | $175.5M | $102.0M | $143.4M | $1,410.6M | $1,527.0M | $1,212.0M | $580.4M | $1,032.3M | $1,702.2M | $2,488.7M | $3,047.6M | $4,162.8M | $6,205.7M | $7,574.4M | $8,930.7M | $9,869.2M |
Discover the top 20 best undervalued stocks to buy for Dec 2024, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Dec 2024, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Dec 2024.
As of today, Vertex Pharmaceuticals Incorporated's last 12-month Revenue is $10.6B, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Vertex Pharmaceuticals Incorporated's Revenue growth was 9.9%. The average annual Revenue growth rates for Vertex Pharmaceuticals Incorporated have been 18.3% over the past three years, 24.0% over the past five years.
Over the last year, Vertex Pharmaceuticals Incorporated's Revenue growth was 9.9%, which is higher than industry growth of 3.0%. It indicates that Vertex Pharmaceuticals Incorporated's Revenue growth is Good.